Could a new pill tame inflammatory bowel disease? early safety trial begins

This Phase 1 trial is testing an experimental oral drug called QLS1510, which is being developed for inflammatory bowel disease (IBD). The study enrolls healthy adults aged 18 to 45 to evaluate the drug's safety, tolerability, how it moves through the body, and the effect of food on its absorption. Participants receive either single or multiple ascending doses of QLS1510 or a placebo, with close monitoring for any side effects. This early-stage research aims to establish a safe dosing range before the drug can be tested in people with IBD.